Showing posts with label Major depressive disorder. Show all posts
Showing posts with label Major depressive disorder. Show all posts

Thursday, April 17, 2014

Psychoneuroimmunology—How Inflammation Affects Your Mental Health

English: Cover of the book Take Control of You...
(Photo credit: Wikipedia)




By Dr. Kelly Brogan
Psychoneuroimmunology. This is what I aim to practice. Medical terms of this length command our respect for the interconnectedness of different subspecialties, for the futile segmentation and compartmentalization of the body into different organ systems.
As discussed in this previous article I wrote for Dr. Mercola, deconstructing the serotonin model of depression, psychiatry is in a crisis. It can no longer stand on its own, throwing more and more medications at its perceived target. 
It seems, therefore, fitting that psychiatry would follow the investigative path of other lifestyle-triggered chronic diseases such as cancer, autoimmunity, and heart disease. There already exists a bidirectional relationship between all of the major chronic diseases and psychiatric diagnoses (patients who struggle with chronic diseases are more likely to be depressed and vice versa). 
The role of inflammation, across these disease states, is better elucidated each day. Let's deconstruct what is known as it applies to mental health.

Inflammation and Depression

In this model, depression is a non-specific fever that tells us little about what is actually causing the body to react and protect itself in this way. The body is "hot" and we need to understand why. Depressive symptoms are the manifestation of many downstream effects on hormones and neurotransmitters, but if we swim up to the source, we will find a river of inflammatory markers coursing by.
The source itself may be singularly or multiply-focused as stress, dietary, and toxic exposures, and infection, as we will discuss here. As explored in the medical literature,1 inflammation appears to be a highly relevant determinant of depressive symptoms such as flat mood, slowed thinking, avoidance, alterations in perception, and metabolic changes. We understand this relationship based on:
Biomarkers  
Psychiatrists have longed to be legitimized in their role as science-based physicians. Despite this, there are no diagnostic tests that are validated for the assessment of psychiatric pathology. In the practice of functional medicine, however, the diagnosis becomes secondary to the individual's personalized interplay of factors and the "biomarkers" that can light the way toward healing. 

Cytokines in the blood, or inflammatory messengers, such as CRP, IL-1, IL-6, and TNF-alpha have taken the stage as predictive2 and linearly3 correlative with depression. 
Researchers have validated4 that, in melancholic depression, bipolar disorder, and postpartum depression, white blood cells called monocytes express pro-inflammatory genes leading to secretion of cytokines, while simultaneously leading to decreased cortisol sensitivity, the body's stress hormone and inflammatory buffer – a feedforward cycle.
Once triggered in the body, these inflammatory agents transfer information to the nervous system, typically through stimulation of major nerves such as the vagus, which connects5 the gut and brain. Specialized cells called microglia in the brain represent the brain's immune hubs and are activated in inflammatory states.
In activated microglia, an enzyme called IDO (indoleamine 2 3-dioxygenase) has been shown6 to direct tryptophan away from the production of serotonin and melatonin and towards the production of an NMDA agonist called quinolinic acidthat may be responsible for symptoms of anxiety and agitation. 

These are just some of the changes that may conspire to let your brain in on what your body may know is wrong.
Animal Models
While an animal model of depression may seem like an absurd idea, currently, lipopolysaccharide (LPS), an endotoxin produced by gram-negative bacteria, is used to induce these clinical models in rodents.
Mice that lack IL1-B7 (a cytokine that mediates inflammatory response), however, are protected against these LPS-mediated "depressive symptoms" (i.e., as demonstrated by loss of interest in sugar water), supporting the critical role of inflammatory messengers in the depressogenic cascade.
Pharmacology
One of the most predictable side effects of interferon therapy for Hepatitis C is depression. In fact, 45 percent of patients develop depression8 with interferon treatment, which appears to be related to elevated levels of inflammatory cytokines IL-6 and TNF.
A number of trials have examined the role of anti-inflammatory agents in the treatment of depression. In one recent trial,9 a subset of patients resistant to antidepressant treatment and identified by serum markers of inflammation, most notably C-reactive protein >3mg/L, were responsive to treatment with the TNF-alpha antagonist (anti-inflammatory) infliximab (Remicade).
The pain-killer celecoxib (Celebrex) has been found in randomized, placebo-controlled trials10 to be superior to placebo in antidepressant augmentation. In the setting of psoriasis treatment with etanercept (Enbrel), mood was improved11independent of psoriatic relief.
There has even been suggestion that the mechanism of action of antidepressants is through an anti-inflammatory effect, particularly on IL6. However, these observational studies have been largely inconclusive.12

The Gut-Brain Dance

What is driving this inflammation? How does it get kicked off? And how does it induce depression? With the limited clinical applications and revelations that came with the completion of the Human Genome Project in 2002, we have begun to focus on where we have outsourced our physiologic functions. 

The microbiome has become an important consideration, and particularly, the gut, which houses at least 10 times as many human cells as there are in our bodies, and 150 times as many genes as are in our genome. These microbes control many vital operations and are responsible for synthesis of neuroactive and nutritional compounds, for immune modulation, and for inflammatory signaling.
Our greatest interface with the environment is the 70+ percent of your immune system housed in your gut wall. Disturbances in gut microbiota, autoimmunity, head injury, childbirth, and infection can all trigger systemic inflammation. This immune activity takes the form of a TH1 dominant cellular response in which macrophages produce ILI, IL6, and TNFalpha, all of which have been shown to be elevated in the setting of depression.
The communication between our guts and brains appears to rely, in part, on the vagus nerve, and is bidirectional in nature as reported in this 12-year prospective study13 that looked at relationships between gut problems like irritable bowel disease, anxiety, and depression.  
The stage is set for the microbiome when we descend the vaginal canal and are breastfed. Unfortunately, the rate of cesarean sections doubled from 1990-2008, comprising one-third of US births. Maternal inflammatory states and diseases such as type 1 diabetes can increase risk of surgical birth, as can interventions such as ultrasound, 14 monitoring, and the epidural.15 Without vaginal transfer of mom's flora, the baby misses out on the most important inoculation.
A study16 of 24 Canadian babies at four months demonstrated that elective section resulted in the most diminished bacterial diversity. Surgically born babies had significantly less Bacteroides and Escherichia-Shigella species. In this cohort, formula-fed babies had overrepresentation of Clostridium difficilePeptostreptococcaceae, and Verrucomicrobiaceae. Excitingly, research is being done on "vaginal swabs" for inoculation in the setting of C-section.17

The Importance of Breast Milk

In our nationwide departure from physiologic birth and breastfeeding, less than one-quarter of women can be expected to be nursing by 12 months postpartumBreast milk18 contains unique nutrients for beneficial bacteria called oligosaccharides, but importantly, it is the vital follow up to the mother's vaginal flora, designed to support the baby's immune system during its infancy marked by an "anti-inflammatory" phenotype. During these first few months, the baby relies on the mother's breast milk to help inform its immune system of what is dangerous.
Over the course of lactation beginning with colostrum, the makeup of these bacteria and growth factors changes.19 A recent study20 confirms that mom's gut bacteria are vertically transferred through breast milk and that this "entero-mammary" connection is what helps to develop the baby's immune system. This is the beginning of natural immunity, which is so much more complex than vaccinologists would have you believe.
One of the many problems with formula is the glaring omission of these microbes leaving the baby susceptible to colonization by inappropriate strains, suboptimal diversity, and stimulation of the immune system by many of the toxic compounds in this synthetic food. In fact, infants fed breast milk had an anti-inflammatory cytokine milieu throughout infancy.21 Here22 is a stunning analysis of formula shortcomings.
Interestingly, this rat study23 demonstrated that the types of bacteria in the guts of these rat pups determined their response to stress on a physiologic level, and that it was more difficult to correct later in their rat-infancy. The gut bacteria influenced behavior and brain growth in these animals. I speak about some of the impediments to adequate milk supply here,24 but formula feeding25in the hospital and "supplementation" is a major offender.

Gluten Promotes Depression

Often processed with genetically modified oils in high glycemic foods, gluten is a brain and body poison. Its havoc begins in the gut, where it promotes intestinal permeability by upregulating a compound called zonulin. Local gut inflammation (often lectin-induced) precedes more systemic inflammatory responses accompanied by antibodies to the different components of gluten (gliadin and glutenin), complexes with enzymes called transglutaminase, and to tissue in the brain, gut, and thyroid through a process called molecular mimicry.
The neurologic effects of gluten intolerance include depression, seizures, headaches, multiple sclerosis/demyelination, anxiety, ADHD, ataxia, neuropathy as discussed here and here. Independent of the brain effects already discussed, gliadin peptides may travel through the blood stream and can stimulate opiate receptors in the brain, resulting in their being termed gliadorphins, accounting for temporary withdrawal symptoms! Get the full scoop in my anti-gluten missive.

The Impact of Unnatural Foods: GMOs

In the past year, there has been an explosion of terrifying information on the impact of herbicides like Monsanto's Roundup (glyphosate) on our gut microbiome. As it turns out, this chemical is very active in slaughtering beneficial bugs in your intestines via its impact on the "shikimate pathway" previously assumed not to exist in humans.
By imbalancing this flora, pesticides/herbicides also disrupt the production of essential amino acids like tryptophan, a serotonin precursor, and promote production of p-cresol, a compound that interferes with metabolism of other "xenobiotics" or environmental chemicals, making the individual more vulnerable to their toxic effects. Even vitamin D3 activation in the liver may be negatively impacted by glyphosate's effect on liver enzymes, potentially explaining epidemic levels of deficiency.
We also have evidence26 that insecticidal toxins such as “Bt” are transferred into the blood of pregnant women and their fetuses, and that glyphosate herbicide transfers to breast milk. Delve27 into this fascinating analysis of what we are learning about these chemicals in our food supply. Genetic modification of foods, in addition to guaranteeing exposure to pest and herbicides, confer risks of gene transference to human gut bacteria, even after a singular exposure.

The Hazards of NSAIDs

Most people think of ibuprofen as an innocuous, over–the-counter comfort for aches and pains. Some are so lulled into a sense of safety and efficacy, that they keep these pills in their purses and nightstands for even daily use. In addition to other known risks, its effects on the small and large intestine may be best summarized by this statement:28
"The initial biochemical local sub-cellular damage is due to the entrance of the usually acidic NSAID into the cell via damage of the brush border cell membrane and disruption of the mitochondrial process of oxidative phosphorylation, with consequent ATP deficiency"
For anyone who recognizes the role of brush border integrity and energy production in health, this is quite a damning assertion. We need the gut lining to keep the gut contents away from the blood stream. Resulting increases in permeability allow for luminal factors (intestinal contents) to access the immune system and to set off autoimmune and inflammatory processes. More recent evidence29 suggests that unbalanced gut bacteria set the stage for NSAID-induced permeability through neutrophil stimulation. These changes occur within three to six months. There are no ways to mitigate these negative effects, which argues for getting to the root of why one is experiencing pain and resolving it through lifestyle change rather than suppressing it with medications that will whack-a-mole their way to new, chronic, and potentially more debilitating symptoms.

The Role of Stress

The monoamine hypothesis of depression has very little to say about brain/hormone interplay. The majority of studies30suggest that depression is associated with high cortisol states, and potentially from responses of this stress-system that were ingrained at birth or before. In the context of inflammation, however, cortisol, prolactin, and sex hormones are often dysregulated; in this model, depression is thought to represent a hypercortisolemic state which may result from elevated levels of inflammatory cytokines. 
Peripheral glucocorticoid resistance may exacerbate this elevation in cortisol (by interfering with feedback mechanisms) and immune response, simultaneously, which would also drive changes in sex hormones progesterone, insulin, and androgens31ultimately affecting mood states. Sleep is often compromised in states of stress, and sleep difficulties can also beget stress. The inflammatory effects of insufficient sleep were quantified in a study32 that deprived participants of sleep (just under six hours) for one week resulting in expression of genes associated with oxidative stress and inflammation.

How to Resolve It—You Feel What You Eat

Restoring optimal gut flora requires a variety of interventions, but beginning with a grain- and dairy-free diet, eliminating sugar, and genetically modified foods is a good place to start. Remember the role of LPS in depression? How depressive patients are more likely to have intestinal permeability allowing for toxic intestinal agents to circulate in their bodies? A traditional/ancestral diet may be an important modulator, according to Selhub et al. who state:33
"Traditional dietary practices have completely divergent effects of blood LPS levels; significant reductions (38%) have been noted after a one-month adherence to a prudent (traditional) diet, while the Western diet provokes LPS elevations."
For some, a FODMAPs diet may be indicated, and for others, a GAPs or Specific Carbohydrate Diet. This dietary approach will also confer the insulin stabilizing benefits of a high-fat, slower burning metabolic shift which protects cortisol, thyroid, and sex hormones. Increasing natural fats may also serve to protect the 60 percent lipid content of the central nervous system, precursors to hormones, and cell membrane composition while stabilizing blood sugar. I discuss three changes to make here.34
Herbs and spices may also play a palliative role in depression through their anti-inflammatory effects. Curcumin, a polyphenol in the Indian spice turmeric with elaborate anti-inflammatory mechanisms was recently found to be as effective as Prozac in small a randomized study I discuss here.35 Fermented foods, a part of traditional cultural diets, would also play a beneficial role, in this paradigm of microbiome-oriented, diet-supported mental health in ways stated here:36
"'This could manifest, behaviorally, via magnified antioxidant and anti-inflammatory activity, reduction of intestinal permeability and the detrimental effects of LPS, improved glycemic control, positive influence on nutritional status (and therefore neurotransmission and neuropeptide production), direct production of GABA, and other bioactive chemicals, as well as a direct role in gut-to-brain communication via a beneficial shift in the intestinal microbiota itself.' In this way, we use bacteria to modify our own bacteria and subsequently dampen inflammatory signals."
The Environmental Working Group (EWG) offers an excellent guide to pesticide-free shopping,37 and a guide38 to avoiding genetically modified foods.

Psychobiotics

In a brilliant review entitled "Psychobiotics: A Novel Class of Psychotropic," Dinan et al tour us through the role of probiotics (therapeutic live organisms ingested as a supplement or as part of a fermented food) in mental health. Acknowledging the data for inflammatory cytokines influencing mood states, and the role of gut bacteria in triggering these cytokines, they review the available literature supporting antidepressant effects of probiotics. There is speculation that anti-inflammatory signaling through IL-10 may underpin probiotic efficacy.
For example, "germ-free" mice exposed to stress experienced normalization of their cortisol response after inoculation withBifidus infantis. In a related experiment testing the stress of maternal separation, adult rodent behavior was normalized with this inoculation despite persistent cortisol changes. Lactobacilli, on the other hand, improved both parameters. In human adults with irritable bowel syndrome, depression and anxiety symptoms improved with administration of Bifidus, and in the setting of chronic fatigue, subjects experienced improvement in anxiety with Lactobacillus casei, relative to placebo. 
In a recent double-blind, placebo-controlled randomized study, subjects receiving B. longum and L. helveticus for 30 days experienced improvement on the Hospital Anxiety and Depression Scale, with decrease in urinary free cortisol. A probiotic-containing yogurt was also found to improve mood within 20 days in elderly volunteers. Intriguingly, a three-arm study39 looked at women consuming a fermented milk beverage three times a day vs milk vs nothing, found that those in the probiotic group had MRI-based changes related to midbrain emotional processing.

The Benefits of Meditation

Activating the relaxation nervous system – the one that allows us to "rest and digest" – is an effective means of easing symptoms and restoring an anti-inflammatory state. You can start with something as simple as listening to a guided meditation for several minutes a day and working up to 20 minutes twice a day for a therapeutic effect.
The interconnectedness of your gut, brain, immune, and hormonal systems is impossible to unwind. Until we begin to appreciate this complex relationship, we will not be able to prevent or intervene effectively in depression, slated to become the second-leading cause of disability in this country, within the decade. For true healing, and meaningful prevention, take steps every day toward sending your body the message that it is not being attacked, it is not in danger, and it is well nourished, well supported, and calm.
As a society, we can begin to think about protecting the microbiome by demedicalizing birth and infant nutrition, and as individuls, by avoiding antibiotics, NSAIDs, grains, genetically modified and non-organic food. Promising interventions for depression from a gut-brain perspective include probiotics, fermented foods as part of a high natural fat diet, and relaxation response for optimal digestion, anti-inflammatory and insulin sensitizing effects. No antidepressant medication required!
Enhanced by Zemanta

Thursday, January 16, 2014

A Psychiatrist’s Perspective on Using Drugs

English: animal medication
 (Photo credit: Wikipedia)



By Kelly Brogan, MD
When I see new patients, I do not prescribe medication for them. Patients who come to me know that I plan to help them understand "why" they are experiencing "what" they are going through. 
Once I have tapered patients off of medication, we use alternatives if symptoms crop up again.
Knowing my basic orientation around the issue of psychiatric prescribing doesn't seem to stop some patients from asking for what they believe will be a quick fix in an antidepressant pill.  Where did they learn to make these treatment requests of providers?
Perhaps they are a reflection of the 49% of requests for drugs prompted by "direct-to-consumer" (DCA) advertising by pharmaceutical companies.1 Fully 7 out of 10 times, doctors prescribe based on these requests made by patients who learned from advertising that they have an "imbalance" that must be fixed with a pill.
In a 10-year period from 1999 to 2008, DCA tripled from 1.3 to 4.8 billion dollars devoted to educating patients about their need for psychiatric medication. The "mass provision" of SSRIs to the public is not a reflection of their well-understood mechanism, of their efficacy, or of their safety. In fact, it flies in the face of all three. 
As stated by Professor of Neuroscience, Elliot Valenstein:2 "What physicians and the public are reading about mental illness is by no means a neutral reflection of all the information that is available."

Reasoning Backwards: What Are We Treating?

If you were to ask the average person on the street what the biology of depression relates to, they would very likely parrot, "serotonin deficiency." This hypothesis, referred to as the monoamine hypothesis, grew out of observations of mood-related side effects in the treatment of tuberculosis patients with iproniazid,3 which has some inhibitory impact on the breakdown of monoamines.
From this accidental observation and double talk about reserpine's role in inducing and treating depressive states, a theory was born.  Six decades of subsequent studies in never-medicated depressed patients have been conflicting, confusing, and inconclusive, and a critical review of the hypothesis concludes:4
" … there is no direct evidence of serotonin or norepinephrine deficiency despite thousands of studies that have attempted to validate this notion."
Similarly conclusive is a New England Journal of Medicine review on Major Depression,5 which stated:
" … numerous studies of norepinephrine and serotonin metabolites in plasma, urine, and cerebrospinal fluid as well as postmortem studies of the brains of patients with depression, have yet to identify the purported deficiency reliably."
Even in the pursuit of this appealingly reductionist idea of a chemical deficiency, we are unable to measure central nervous system quantities, to account for the inner workings of 14 different types of serotonin receptors,
Also for the vast projections of serotonin trafficking neurons, and for the delicate interplay between the 100 some neurotransmitters that we know to be active in the brain. Dr. Daniel Carlat, author of Unhinged, writes:
"We have convinced ourselves that we have developed cures for mental illnesses…when in fact we know so little about the underlying neurobiology of their causes that our treatments are often a series of trials and errors."

How Do These Meds Work?

Even if we were to accept the premise that these medications are helpful, extrapolating a medical etiology from this observation would be the same as saying that shyness is a deficiency of alcohol, or migraine a deficiency of codeine.
And to my holistic and integrative colleagues who are very excited about tryptophan and 5HTP in medication-naïve patients, I will remind them that the only time that tryptophan depletion has correlated with low mood is in those patients previously treated with SSRIs.
We have been taught to associate serotonin with feeling good, but the fact is that high serotonin has been associated with feeling bad, including carcinoid syndrome, Alzheimer's, autism, and schizophrenia.
Low serotonin metabolite (5H1AA) is indicative of turnover of serotonin, and is the eventual result of increased serotonin in the synapse. This has been associated with suicide, violent crime, alcoholism, bulimia, and exhibitionism! Clearly, we are not dealing with a simple more is better, or even a "looking for the right balance" type of scenario.
Chasing this pattern and seeking to alter "levels" is like trying to connect a pile of scattered dots into a long straight line – you have to ignore the ones that don't fit.What about genetics? Wasn't I born with this defect?
Despite the continued efforts to identify "the gene," a false start in 2003,6 which suggested that those with a variant in the serotonin transporter were 3x more likely to be depressed, was later mowed over by a meta-analysis of 14,000 patients that denied this association.7  Dr. Insel, head of the NIMH, had this to say:
"Despite high expectations, neither genomics nor imaging has yet impacted the diagnosis or treatment of the 45 million Americans with serious or moderate mental illness each year."
Carlat goes on to say: "And where there is a scientific vacuum, drug companies are happy to insert a marketing message and call it science. As a result, psychiatry has become a proving ground for outrageous manipulations of science in the service of profit."

Pharma Weaves an Irresistible Tale

Eleven billion dollars are spent each year on antidepressant medications,8 pharmaceutical companies have 625 lobbyists,9 and they underwrite more than 70% of FDA trials. They court physicians,10 give them samples, tell patients to "ask their doctor," pay consultants to speak at scientific meetings, advertise in medical journals, fund medical education, and ghostwrite, cherry pick and redundantly submit data for publication.  Psychiatric studies funded by pharma are 4x more likely to be published if they are positive,11 and only 18% of psychiatrists are disclosing their conflicts of interests when they publish data. Their studies allow:
  • Placebo washout (getting rid of those who are likely to respond to placebo before the study to strengthen the perceived benefit)
  • Replacement of non-responders
  • Breaking blind by using inert placebos so that subjects know that they have received the treatment
  • Use of sedative medications concurrent to study medications
A now famous 2008 study in the New England Journal of Medicine12 by Turner et al sought to expose the extent of data manipulation. Through valiant efforts to uncover unpublished data, they determined that from 1987 to 2004, 12 antidepressants were approved based on 74 studies. 38 were positive, and 37 of these were published.  Thirty-six were negative (showing no benefit), and 3 of these were published as such while 11 were published with a positive spin (always read the data not the author's conclusion!), and 22 were unpublished.
Since two studies are required by the FDA for approval, you can see how these companies are tossing the coin repeatedly, until heads comes up, and hoping no one is looking when it's tails. Per Robert Whitaker, author of Anatomy of An Epidemic and Mad In America, references, these practices undermine the accuracy of data and deliver information that corrupts physician's delivery of care and endangers patients.
The costs of this manipulation of information is the loss of true informed consent – physicians cannot adequately share with patients the risks and benefits if the benefits are fabricated and the risks are not uncovered (by 5-6 week trials) or are unacknowledged.

Placebo Effect – Why They "Work"

Despite Pharma's efforts, the truth about these brain bombs is emerging. In 1998, Dr. Irving Kirsch, an expert on the placebo effect, published a meta-analysis13 of 3,000 patients who were treated with antidepressants, psychotherapy, placebo, or no treatment and found that 27% of the therapeutic response was attributable to the drug's action. 
This was followed up by a 2008 review,14 which invoked the Freedom of Information Act to obtain access to unpublished studies, finding that, when these were included, antidepressants outperformed placebo in only 20 of 46 trials (less than half!), and that the overall difference between drugs and placebos was 1.7 points on the 52 point Hamilton Scale.  This small increment is clinically insignificant, and likely accounted for my medication side effects strategically employed (sedation or activation).
He found that severely depressed patients were less placebo responsive, generally, potentially accounting for the impression of some increased benefit, such as that found by Fournier et al.15 When active placebos were used, the Cochrane database16 found that differences between drugs and placebos disappeared, given credence to the assertion that inert placebos inflate perceived drug effects.
In response to 2005 recommendations from the National Institute for Health and Clinical Excellence that SSRI medications be first line treatment recommendations for depression, Drs. Kirsch and Moncrieff pointed out17 that the NICE data, itself, demonstrates a 1 point difference on the 52 point Hamilton Scale between placebo and drug groups, and that it was not in more severely depressed patients that this was found.
The finding of tremendous placebo effect was also echoed in two different meta-analysis by Khan et al18 who found a 10% difference between placebo and antidepressant efficacy, and comparable suicide rates. The largest, non-industry funded study,19costing the public $35 million dollars, followed 4000 patients treated with Celexa (not blinded, so they knew what they were getting), and half of them improved at 8 weeks. Those that didn't were switched to Wellbutrin, Effexor, or Zoloft OR "augmented" with Buspar or Wellbutrin.
Guess what? It didn't matter what was done, because they remitted at the same unimpressive rate of 18-30% regardless. Only 3% of patients were in remission at 12 months.
So what if it's placebo effect? It's working at least some of the time, so who cares? Here's why I, and other concerned psychiatrists and practitioners, care: I first became aware of the habit forming nature of these medications when I tapered a patient off of Zoloft in anticipation of a pregnancy in the coming year, and she experienced about 6 months of protracted withdrawal that began at about two months after the last dose. This was nothing I was prepared, by my training, to deal with. 
What are these medications actually doing?!  The truth is, we have very little idea. We like to cling to simple explanations, but even the name of the various antidepressants, selective serotonin reuptake inhibitors and norepinephrine reuptake inhibitors is misleading.
They are far from selective.  An important analysis20 by the former director of the NIMH makes claimed that antidepressants "create perturbations in neurotransmitter functions" causing the body to compensate through a series of compensatory adaptations which occur after "chronic administration" leading to brains that function, after a few weeks, in a way that is "qualitatively as well as quantitatively different from the normal state."
Changes in beta-adrenergic receptor density, serotonin autoreceptor sensitivity, and serotonin turnover all struggle to compensate for the assault of the medication.
Andrews et al21 calls this "oppositional tolerance," and demonstrate through a careful meta-analysis of 46 studies demonstrating that patient's risk of relapse is directly proportionate to how "perturbing" the medication is, and is always higher than placebo (44.6% vs 24.7%). They challenge the notion that findings of decreased relapse on continued medication represent anything other than drug-induced response to discontinuation of a substance to which the body has developed tolerance. They go a step further to suggest:
"For instance, in naturalistic studies, unmedicated patients have much shorter episodes, and better long-term prospects, than medicated patients (Coryell et al., 1995; Goldberg et al., 1998; Posternak et al., 2006). Several of these studies have found that the average duration of an untreated episode of major depression is 12–13 weeks (Coryell et al., 1995; Posternak et al., 2006).
Since acute ADM management of major depression minimally requires several weeks to reduce symptoms, the duration of untreated episodes is much shorter than the recommended duration of ADM therapy. This suggests that ADM therapy may delay resolution of depressive episodes."
Harvard researchers22 also concluded that at least fifty percent of drug-withdrawn patients relapsed within 14 months. In fact:
"Long-term antidepressant use may be depressogenic . . . it is possible that antidepressant agents modify the hardwiring of neuronal synapses (which) not only render antidepressants ineffective but also induce a resident, refractory depressive state."23

Buyer Beware

Here we come to the little disclosed poor outcomes associated with long-term treatment. We won't focus on the risk of suicide and violence, bleeds, or even suppressed libido and sexual dysfunction, indifference (or "medication spell-binding" as Dr. Peter Breggin calls it), or weight gain and dysglycemia.  Let's just focus on what the data shows on how your ability to function, long-term, in the world with depression is significantly sabotaged by treating that first episode of depression with medication.
This was famously explored by Robert Whitaker, and can be summarized with the following studies, as a primer. Longitudinal studies demonstrate poor functional outcomes for those treated with 60% of patients still meeting diagnostic criteria at one year24 (despite transient improvement within the first 3 months). When baseline severity is controlled for, two prospective studies support a worse outcome in those prescribed medication:
One in which the never-medicated group experienced a 62% improvement by six months, whereas the drug-treated patients experienced only a 33% reduction in symptoms,25 and another WHO study of depressed patients in 15 cities which found that, at the end of one year, those who weren't exposed to psychotropic medications enjoyed much better "general health;" that their depressive symptoms were much milder;" and that they were less likely to still be "mentally ill."26
I'm not done yet. In a retrospective 10-year study27 in the Netherlands, 76% of those with unmedicated depression recovered without relapse relative to 50% of those treated. Unlike the mess of contradictory studies around short-term effects, there are no comparable studies that show a better outcome in those prescribed antidepressants long term.
Perhaps most concerning to a holistic physician is data28 that suggests that long-term antidepressant treatment actually compromises the known and evident benefits29 of exercise! Benefits of exercise treatment of depression were comparable to Zoloft and were diminished when combined with Zoloft where patients relapsed at higher rates than they did with exercise alone.

Selling Sickness

Whitaker helps us to remember: Prior to the widespread use of antidepressants, the National Institute of Mental Health told the public that people regularly recovered from a depressive episode, and often never experienced a second episode.30 Now we have skyrocketing rates of disability in the setting of skyrocketing prescriptions. Whitaker has compiled and analyzed data demonstrating that days of work lost are increased by medication treatment as is long-term disability (19% vs 9%),31 3-7 times the incidence of loss of "principal social role" and "incapacitation,"32 with treated illness, and that 85% of unmedicated patients recover in a year, with 67%33 doing so by 6 months – an enviable statistic.
What has happened here? Since its 1952 inception and notorious inclusion of homosexuality as a diagnosable syndrome, the Diagnostic and Statistical Manual has now ballooned to more than 300 diagnoses in its fifth edition, all arrived at through general consensus of a committee consisting of practitioners with conflicts of interest34 and pharmaceutical enmeshments. Allen Frances at Columbia states:
"Wholesale imperial medicalization of normality that will trivialize mental disorder and lead to a deluge of unneeded medication treatment – a bonanza for the pharmaceutical industry but at a huge cost to the new false positive patients caught in the excessively wide DSM-V net." 
We need to break the populace out of its spell, reject the serotonin meme, and start looking at depression (and anxiety, and bipolar, and schizophrenia, and OCD, etc) for what they are – disparate expressions of a body struggling to adapt to a stressor. We need to identify vulnerabilities, modifiable exposures, and support basic cellular function, detox, and immune response. This is personalized medicine, where these abstract labels become meaningless because they only address the "what" of the symptoms" in an impressionistic, non-specific manner.  One as helpful as saying the fever is the disease, and Tylenol the cure. Psychiatry's swan song has been sung…listen for its plaintive wail. 

About the Author

Dr. Brogan is boarded in Psychiatry/Psychosomatic Medicine/Reproductive Psychiatry and Integrative Holistic Medicine, and practices Functional Medicine, a root-cause approach to illness as a manifestation of multiple-interrelated systems.  After studying Cognitive Neuroscience at M.I.T., and receiving her M.D. from Cornell University, she completed her residency and fellowship at Bellevue/NYU.  She is one of the only physicians with perinatal psychiatric training who takes a holistic evidence-based approach in the care of patients with a focus on  environmental medicine and nutrition. She is also a mom of two, and an active supporter of women's birth experience, rights to birth empowerment, and limiting of unnecessary interventions which is a natural extension of her experience analyzing safety data and true informed consent around medical practice.  She is the Medical Director for Fearless Parent, and an advisory board member for GreenMedInfo.com and Pathways to Family Wellness. She practices in NYC and is on faculty at NYU/Bellevue. 
Enhanced by Zemanta